BIIB vs ESPR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and ESPR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- ESPR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while ESPR’s TA Score has 3 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 4 bearish.
- ESPR’s TA Score: 3 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -2.10% price change this week, while ESPR (@Pharmaceuticals: Other) price change was -9.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.19%. For the same industry, the average monthly price growth was +5.80%, and the average quarterly price growth was -6.59%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.21%. For the same industry, the average monthly price growth was +11.99%, and the average quarterly price growth was +4.71%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
ESPR is expected to report earnings on Aug 05, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-1.19% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Other (-1.21% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BIIB | ESPR | BIIB / ESPR | |
| Capitalization | 31.3B | 496M | 6,310% |
| EBITDA | 2.04B | -150.11M | -1,358% |
| Gain YTD | -22.580 | -59.418 | 38% |
| P/E Ratio | 26.95 | N/A | - |
| Revenue | 9.84B | 116M | 8,479% |
| Total Cash | 1.05B | 82.2M | 1,277% |
| Total Debt | 7.34B | 266M | 2,759% |
BIIB | ESPR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 35 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 66 | 98 | |
PRICE GROWTH RATING 1..100 | 64 | 94 | |
P/E GROWTH RATING 1..100 | 97 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ESPR's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for BIIB (88). This means that ESPR’s stock grew somewhat faster than BIIB’s over the last 12 months.
ESPR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that ESPR’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's SMR Rating (66) in the Biotechnology industry is in the same range as ESPR (98). This means that BIIB’s stock grew similarly to ESPR’s over the last 12 months.
BIIB's Price Growth Rating (64) in the Biotechnology industry is in the same range as ESPR (94). This means that BIIB’s stock grew similarly to ESPR’s over the last 12 months.
BIIB's P/E Growth Rating (97) in the Biotechnology industry is in the same range as ESPR (100). This means that BIIB’s stock grew similarly to ESPR’s over the last 12 months.
| BIIB | ESPR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 48% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 87% |
| Advances ODDS (%) | 9 days ago 53% | 9 days ago 84% |
| Declines ODDS (%) | 3 days ago 71% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 89% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| WLGRX | 31.77 | 0.19 | +0.60% |
| Macquarie Large Cap Growth Fund R | |||
| SSTFX | 10.46 | N/A | N/A |
| Virtus KAR Capital Growth C | |||
| YASSX | 10.29 | N/A | N/A |
| AMG Yacktman Special Opportunities I | |||
| ILGJX | 20.34 | N/A | N/A |
| Columbia Integrated Large Cap Gr Ins 3 | |||
| WASYX | 22.13 | -0.03 | -0.14% |
| Macquarie Asset Strategy Fund Cl Y | |||
BIIB and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +1.01% | ||
| AMGN - BIIB | 48% Loosely correlated | -1.37% | ||
| NVS - BIIB | 47% Loosely correlated | -1.41% | ||
| PFE - BIIB | 45% Loosely correlated | +0.79% | ||
| SNY - BIIB | 39% Loosely correlated | -0.27% | ||
| AZN - BIIB | 39% Loosely correlated | -3.95% | ||
More | ||||
ESPR and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with ALKS. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then ALKS could also see price increases.
| Ticker / NAME | Correlation To ESPR | 1D Price Change % | ||
|---|---|---|---|---|
| ESPR | 100% | +2.51% | ||
| ALKS - ESPR | 33% Loosely correlated | N/A | ||
| PTPI - ESPR | 29% Poorly correlated | -15.16% | ||
| DVAX - ESPR | 29% Poorly correlated | -0.31% | ||
| ZOMDF - ESPR | 26% Poorly correlated | -2.44% | ||
| EVO - ESPR | 26% Poorly correlated | -6.24% | ||
More | ||||